DRRX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Stats
Tagesvolumen	59 768.00
Durchschnittsvolumen	163 685
Marktkapitalisierung	29.60M
EPS	$0 ( 2024-03-27 )
Nächstes Ertragsdatum	( $-0.210 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.790
ATR14	$0.0130 (1.38%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-21	Robertson Judith J.	Buy	5 500	Stock Option (right to buy)
2023-06-21	Maderis Gail J	Buy	5 500	Stock Option (right to buy)
2023-06-21	Garcia Peter S	Buy	5 500	Stock Option (right to buy)
2023-06-21	Farfel Gail M	Buy	5 500	Stock Option (right to buy)
2023-06-21	Blaschke Terrence F	Buy	5 500	Stock Option (right to buy)

INSIDER POWER
99.16
Last 97 transactions
Buy: 5 988 954 \| Sell: 1 498 606

Volumen Korrelation

Lang: -0.10 (neutral)

Kurz: -0.24 (neutral)

Signal:(45.04) Neutral

DURECT Corp Korrelation

10 Am meisten positiv korreliert
APOP	0.917
RMRM	0.903
GAINL	0.885
KTRA	0.87
TDAC	0.859
PASG	0.858
VXRT	0.853
ADMA	0.851
GLMD	0.846
VVOS	0.841

10 Am meisten negativ korreliert
BOCH	-0.926
MMAC	-0.878
SHSP	-0.857
NETE	-0.855
DSPG	-0.837
LINK	-0.824

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

DURECT Corp Korrelation - Währung/Rohstoff

0.24
( neutral )

0.37
( neutral )

0.00
( neutral )

-0.26
( neutral )

0.12
( neutral )

DURECT Corp Finanzdaten

Annual	2023
Umsatz:	$8.55M
Bruttogewinn:	$6.83M (79.91 %)
EPS:	$-1.050

FY	2023
Umsatz:	$8.55M
Bruttogewinn:	$6.83M (79.91 %)
EPS:	$-1.050

FY	2022
Umsatz:	$19.28M
Bruttogewinn:	$17.70M (91.76 %)
EPS:	$-1.560

FY	2021
Umsatz:	$13.98M
Bruttogewinn:	$12.02M (86.01 %)
EPS:	$-0.0161

Financial Reports:

No articles found.

DURECT Corp

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.